Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Shares Outstanding (Diluted Average) (2023 - 2025)

BioNexus Gene Lab's Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $1.8 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $1.8 million for Q3 2025, up 1.12% from a year ago — trailing twelve months through Sep 2025 was $1.8 million (up 1.12% YoY), and the annual figure for FY2024 was $17.8 million, up 12.24%.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $1.8 million at BioNexus Gene Lab, roughly flat from $1.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $18.0 million in Q1 2025 to a low of $1.8 million in Q2 2024.
  • The 3-year median for Shares Outstanding (Diluted Average) is $8.8 million (2023), against an average of $9.6 million.
  • The sharpest move saw Shares Outstanding (Diluted Average) grew 12.24% in 2024, then rose 1.12% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $15.9 million in 2023, then grew by 12.24% to $17.8 million in 2024, then crashed by 89.92% to $1.8 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $1.8 million, $1.8 million, and $18.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.